China Pharma Holdings, Inc. (CPHI) is a biopharmaceutical firm focused on the development, manufacturing, and marketing of products for treating cardiovascular, CNS, and digestive disorders. The products of the company include cerebroprotein hydrolysate for memory decline, gastrodin for loss of concentration, propyl gallate for cerebral thrombosis, bumetanide for edema, and candesartan for hypertension.
The price of CPHI stock during the regular trading on February 3, 2022, was $0.49 with a 17.2% gain. At last check in the premarket on February 4, 2022, the stock further jumped by 10.1%.
CPHI: Key Financials
On November 12, 2021, CPHI released its financial results for the quarter ended September 30, 2021. Some of the key features are discussed below.
Revenue
Revenue recorded in Q3 2021 was $2.0 million compared to $2.4 million in the same period of 2020. A decline of 17.6% was observed in the revenue over the period of the year. The decline in the revenue was the result of the extension of the national centralized drug acquisitions scope and the associated price drop. The financial analysts also observed that the company missed the estimated revenue target by $307.2 thousand.
EPS
Basic and diluted net loss per share in Q3 2021 was $0.8 million or $0.02 compared to $1.0 million or $0.02 in the same quarter of 2020. The net loss was reduced over the period of the year due to a reduction in selling costs in 2021. The company missed the estimated EPS by $0.04/
CPHI: CEO Comments
Speaking at the occasion, CPHI CEO Zhilin Li stated that the company focused on the consistency assessment of its registered products in the quarter. He further added that the company’s lead product Candesartan had passed the consistency assessment test. The company had submitted the application resources to the National Medical Products Administration.
Conclusion
CPHI stock is 45% down the past six months due to economic restraints caused as a result of the pandemic. The company’s stock is in a good position in the recent premarket due to uncertain factors as no official statement, SEC filing, or forthcoming event is listed on the company’s website.
